Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business
  • interests

Trending on Bing

'Arms-for-food deal'
Alleged victim's texts
Soaring home run
Concealed guns permit
Ridley-Thomas guilty
May return to Pacific
Removes over 5k tweets
Declares NBA draft
Aniston on 'Friends'
Jetson tech recalled
'Abortion trafficking'
Chinese hacking group
Ky. sports betting
Ford hikes prices
Evacuation lifted
Consider obesity drugs
Plants make some noise
COVID shots for kids
Trans rights protests
E3 cancels 2023 event
Mets' Opening Day win
2017 Vegas shooting
OK's 4% tuition hike
Finland to join NATO
Ratings plummet 61%
Blocks DeSantis' power
Lips like a lizard?
LFO member dies at 47
Bam Margera arrested
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
753 results
Becker's Hospital Review13d
Amgen to lay off 450
Amgen, a drugmaker based in Thousand Oaks, Calif., will lay off 450 people — 2 percent of its workforce — with many separations occurring by May 26, according to a statement shared with Becker's.
Wall Street Journal4d
Amgen Seeks to Monopolize Nature
On Monday the Supreme Court will hear oral arguments in Amgen v. Sanofi, a case with immense potential consequences for scientific innovation. If the high court upends settled patent law by ...
1don MSN
Amgen Options Traders Betting On Stock Rising This Much By April Expiration
Amgen Inc. (NASDAQ: AMGN) is expected to report quarterly earnings at $4 per share on revenue of $6.26 billion, analysts say.
Becker's Hospital Review3d
Digital therapeutics company lays off 35% of workforce
Better Therapeutics, a digital therapeutics company, laid off 35 percent of its workforce, according to a March 23 filing with the U.S. Securities and Exchange Commission. According to an end-of ...
4don MSN
Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court
The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a "blatant attempt" to ...
Seeking Alpha6d
Amgen: Questioning The Horizon Therapeutics Acquisition
Amgen reported solid results for fiscal 2022 with the bottom line growing in the double digits. The company recently announced the acquisition of Horizon Therapeutics and while the acquisition ...
IPWatchdog4d
What I’ll Be Watching for in the Amgen Oral Arguments
“I suspect that, no matter what the Court does, the need for excellent lawyering on the enablement question in future cases is not going away. A clear statement of the test is not going to ...
Computing2d
Twilio lays off 930 employees: 5 big things to know
Twilio is laying off nearly 1,000 employees, as the cloud communications specialist says it simply grew too fast and needs to focus on profitability and core priorities. However, some of the sta ...
CNBC7d
Walmart lays off hundreds of workers at e-commerce facilities
Walmart is laying off hundreds of employees at e-commerce fulfillment centers across the country. The big-box giant joins a growing list of retailers, including Amazon and Target, that are cutting ...
Business Insider7d
Influencer-marketing platform Grin lays off staffers across marketing, engineering, and more teams: 'Unfair and unexpected'
Grin, a marketing platform used by brands to run sponsored campaigns with influencers on social media, is the latest creator-economy startup to lay off employees. On Tuesday, the company laid off ...
Reuters3d
U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents
"We're better off with two competing independently developed therapies," Clement said. Clement said allowing Amgen's broad patents would freeze out other companies. The justices focused their ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback